6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes
US11077113B2 · kind B2 · utility
0Cited by
0References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 17, 2017 |
| Grant date | Aug 3, 2021 |
| Priority date | — |
| Expiry date | Jun 21, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides novel 6-aryl or 6-heteroaryl 4-morpholin-4-yl-pyhdine-2-one compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, diabetes, inflammatory diseases, neurodegenerative disorders, cardiovascular disorders and viral infections; wherein R1, R2, R3 and R4 are as defined in the specification.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.